BeiGene cancer drug misses mark in Phase III study

China based BeiGene,  a commercial-stage biopharmaceutical company focused on developing and commercializing innova...

December 20, 2019 | Friday | News
Takeda, Turnstone Biologics to develop novel viral immunotherapies

US based Turnstone Biologics, a biotechnology company pioneering the development of engineered viral immunotherapies,&nb...

December 20, 2019 | Friday | News
European Commission approves Roche’s breast cancer drug

Roche has announced that the European Commission has approved Kadcyla® (trastuzumab emtansine) for the adjuvant (aft...

December 19, 2019 | Thursday | News
Pfizer, Astellas' Xtandi Gets FDA nod

Pfizer and Japan based Astellas Pharma have announced that the U.S. Food and Drug Administration (FDA) has approved a su...

December 17, 2019 | Tuesday | News
AstraZeneca, Daiichi Sankyo’s trastuzumab shows promise in Phase II Trial

AstraZeneca and Daiichi Sankyo Company presented positive detailed data from the global pivotal Phase II single-arm DEST...

December 16, 2019 | Monday | News
Brii Biosciences expands focus to neurosciences

Brii Biosciences, a clinical-stage company committed to serving patients’ needs and improving public health in Chi...

December 4, 2019 | Wednesday | News
Innovent, Eli Lilly presents co-developed cancer-fighting Tyvyt at CIIE 2019

Innovent Biologics, a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Ty...

December 2, 2019 | Monday | News
Chugai Pharma's study on satralizumab published in The New England Journal of Medicine

 Chugai Pharmaceutical has announced that the "New England Journal of Medicine" (NEJM) online edition November 27 R...

December 2, 2019 | Monday | News
Astellas to treat men with metastatic castration-resistant prostate cancer in China

Astellas Pharma Inc.,  based in Tokyo, Japan has announced the China National Medical Products Administration ...

November 26, 2019 | Tuesday | News
Pfizer Unveils Positive Results for VIZIMPRO® as first-line monotherapy in NSCLC patients

Pfizer Inc. on 25th Nov 2019, announced the efficacy and tolerability results from the subgroup analysis of Asian patien...

November 26, 2019 | Tuesday | News
Merck presented Data on Tepotinib for NSCLC at ESMO Asia 2019

Merck, a leading science and technology company, on 25 Nov 2019, announced the presentation of multiple abstracts on tep...

November 25, 2019 | Monday | News
BeiGene receives its first FDA approval

BeiGene, Ltd., China, a commercial-stage biopharmaceutical company focused on developing and commercializing innovative ...

November 18, 2019 | Monday | News
Yuhan Pharmaceuticals partners with Cyclica

South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology c...

November 13, 2019 | Wednesday | News
China approves Alzheimer's drug

The State Food and Drug Administration of China (CFDA) has conditionally approved the application for the listing o...

November 11, 2019 | Monday | News
Samsung Biologics collaborates with Ichnos Sciences in derma space

South Korea headquartered Samsung Biologics has announced the signing of a long-term agreement with US based Ichnos Scie...

November 6, 2019 | Wednesday | News
EU approves BAVENCIO® (avelumab) Plus Axitinib to treat RCC

Merck and Pfizer Inc. on 29 Oct 2019, announced that the European Commission (EC) has approved BAVENCIO® (avelu...

October 29, 2019 | Tuesday | News
Biogen plans regulatory filing for Aducanumab for Alzheimer's

Biogen and Eisai, Co., Ltd. (Tokyo, Japan) has announced that, after consulting with the U.S. Food and Drug Administrati...

October 23, 2019 | Wednesday | News
Takeda acquires license for celiac disease therapy

Japanese firm Takeda Pharmaceutical Company  and US based COUR Pharmaceutical Development Company, Inc. have announ...

October 22, 2019 | Tuesday | News